Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
December 2018
-
Press Release
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor… -
Story Discovery
From patient to patient advocate: how a cancer diagnosis fueled a new career path
Elyse Spatz Caplan’s cancer diagnosis impacted her life in more ways than 1
-
Press Release
Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data
PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients[1],[2] Ligelizumab (QGE031), a monoclonal antibody… -
Press Release
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative… -
Press Release
Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies
Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic… -
Press Release
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration… -
Press Release
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patientsCrizanlizumab, a monthly infusion…
November 2018
-
Press Release
Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free… -
Featured News
Discussing innovative solutions to address unmet healthcare needs in Asia
-
Press Release
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1] Ziextenzo is indicated… -
Press Release
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
Alcon is the global leader in the highly attractive and growing $23 billion eye care devices market Market leading development capabilities and innovation investments Clearly defined near and… -
Story Discovery
An up-close look at cryo-electron microscopy
Scientists are using the imaging technique to see complex molecular structures in stunning detail.